Recursion said it expects to launch its first registrational trial in the second half of 2027 for REC-4881 after positive Phase Ib/II data in familial adenomatous polyposis (FAP). The results were tied to an updated readout from the TUPELO trial (NCT05552755), showing reductions in both larger, higher-risk polyps and overall lower GI polyp burden. REC-4881 is an oral allosteric inhibitor of MEK1 and MEK2. Recursion is developing it under a global licensing agreement with Takeda, which originally developed the asset as TAK-733 and used Recursion’s AI platform to identify targeted oncology applications. For FAP, the standard remains lifelong endoscopic surveillance and eventual prophylactic surgery, leaving a clear unmet need for pharmacologic approaches. Recursion said it is in discussions with the FDA and that the registrational timeline depends on those regulatory interactions and additional details to be shared later this year. The company emphasized that the updated clinical data represent its strongest evidence point that REC-4881 can move the strategy forward in a chronic, lifelong indication where efficacy endpoints matter across the bowel. Investors will likely track how Recursion defines success criteria for a registration-directed trial and whether histologic or burden-reduction measures become central to the regulatory pathway.